Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
Non-Hodgkin's Lymphoma
BIOLOGICAL: single dose of CNCT19
Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR), Efficacy of CNCT19 as measured by ORR at the 3 months after CNCT19 Cell Injection infusion, which includes CR and PR., At 3 months after infusion
CR rate at 3 months after CNCT19 infusion, Efficacy of CNCT19 as measured by CR during the 3 months after CNCT19 Cell Injection infusion., 3 months|ORR（CR+PR）/CR, 28 days|ORR（CR+PR）/CR, 6 months|Progression-free survival (PFS), PFS means duration from the CNCT19 Cell Injection infusion to progression of lymphoma, or death for any reason., 24 months|Disease-free survival (DFS), DFS means duration from the beginning of complete remission to relapse of disease, or death (for any reason)., 24 months|Duration of Remission (DOR), DOR means the duration from reaching the response (e.g., CR or PR) criteria of the therapy to the first, clearly defined progressive disease, or death for disease under investigation., 24 months|Best Overall Response (BOR), The best overall response after CNCT19 infusion., 24 months|Overall Survival (OS), OS means duration from the CNCT19 Cell Injection infusion to death for any reason, or the last follow-up for survival., 24months|Time to remission (TTR), TTR means duration from the CNCT19 Cell Injection infusion to the first response (irrespective of PR or CR, which comes first)., 24 months
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL. The study consists of screening period (8 weeks), treatment period (4 weeks), and follow-up period (2 years at most).